(Sharecast News) - Drugmaker GSK said on Tuesday that the European Commission has approved its asthma and nasal polyps treatment Exdensur (depemokimab) for two separate indications.
GSK said the regulator had cleared the drug as an add‑on maintenance therapy for adults and adolescents with severe asthma driven by type 2 inflammation...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE